Filing Flows › Castle Biosciences (CSTL) › Q2 2026 › vs Q2 2025
Castle Biosciences (CSTL) Q2 2026 vs Q2 2025 (year over year)
Castle Biosciences's revenue rose $17.4M (+20%) from $86.2M in Q2 2025 to $104M in Q2 2026. The biggest changes: Non-Dermatologic +$25.0M (+83%); Dermatologic −$7.6M (-13%).
Castle Biosciences, Q2 2026: revenue $104M (+20% year over year), operating margin -3.0%, net loss $2.1M, operating cash flow $15.2M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 6.3% | 13.4% | -7.1 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Non-Dermatologic | $54.8M | $29.9M | $25.0M | +83% |
| Dermatologic | $48.7M | $56.3M | −$7.6M | -13% |
| Revenue | $104M | $86.2M | $17.4M | +20% |
| Other income, net | $1.4M | $4.1M | −$2.7M | -66% |
| Net loss | $2.1M | −$4.5M | $6.6M | — |
| Costs & expenses | $107M | $95.0M | $12.0M | +13% |
| Operating costs | $107M | $90.4M | $16.2M | +18% |
| Income tax | $370K | −$4.7M | $5.0M | — |
| Cost of revenue | $23.7M | $17.6M | $6.1M | +34% |
| Research & development | $14.5M | $12.8M | $1.8M | +14% |
| SG&A | $66.1M | $58.1M | $8.1M | +14% |
| Other operating costs | $2.3M | $2.0M | $290K | +15% |
| Operating cash sources | $17.3M | $16.3M | $963K | +6% |
| Depreciation & amortization | $4.1M | $3.4M | $656K | +19% |
| Share-based compensation | $11.6M | $11.2M | $381K | +3% |
| Working capital & other | $1.6M | $1.7M | −$74K | -4% |
| Net loss absorbed | $2.1M | −$4.5M | $6.6M | — |
| Operating cash flow | $15.2M | $20.8M | −$5.6M | -27% |
| Free cash flow (OCF − capex) | $6.6M | $11.6M | −$5.0M | -43% |
| Capital expenditures | $8.7M | $9.3M | −$613K | -7% |
Questions
How much did Castle Biosciences's revenue grow year over year in Q2 2026?
Castle Biosciences's revenue rose $17.4M (+20%) from $86.2M in Q2 2025 to $104M in Q2 2026.
What drove Castle Biosciences's revenue change in Q2 2026?
Non-Dermatologic +$25.0M (+83%); Dermatologic −$7.6M (-13%).